In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sabry Takes BD Reins at Roche's gRED

Executive Summary

The recent appointment of James Sabry, MD, PhD, as Genentech's new head of business development is Roche's latest attempt to retain the spirit of the once-independent biotech icon.

You may also be interested in...

Genentech's New Deal Maker

In a wide-ranging interview just four days after joining Genentech, the biotech's new head of business development outlines his team's mission, which emphasizes early-stage novel assets arising from academia and biotech.

Business Development at Roche and Genentech: An Interview with Joe McCracken and Dan Zabrowski

What does Roche's privatization of Genentech mean for the companies' business development organizations and current and future partners? We recently sat down with the company's two business development chiefs to find out.

QUOTED. 3 March 2021. Greg Dadika.

Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts